Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Source: 
Fierce Pharma
snippet: 

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial. Now, the drugmaker hopes a new study from the National Institutes of Health will change that.